Zimmer Biomet Stock Price, News & Analysis

Zimmer Biomet Holdings has announced that its first-quarter earnings conference call will be webcast on May 2, 2023, at 8:30 a.m. ET. A news release featuring the quarterly results will be available on the same day at 6:30 a.m. ET. The event will be accessible on Zimmer Biomet's Investor Relations website. Interested U.S. and Canadian participants can join by calling (888) 204-4368, while international callers should dial +1 (323) 994-2093, both using conference ID 5103691. Zimmer Biomet continues to lead in medical technology, aiming to enhance patient mobility and health through innovative products and technologies.

Zimmer Biomet Holdings, a global leader in medical technology, has approved a cash dividend of $0.24 per share for Q1 2023. This dividend will be payable on April 28, 2023, to stockholders of record by the close of business on March 29, 2023. The company's commitment to returning value to shareholders demonstrates its financial health and confidence in future growth. With over 90 years in the industry, Zimmer Biomet continues to enhance patient experiences through innovative products and advanced technologies.

Zimmer Biomet (NYSE: ZBH) announced the unveiling of enhancements to its ZBEdge™ Dynamic Intelligence™ at the AAOS 2023 Annual Meeting in Las Vegas. Key updates include the mymobility® Digital Care Management Platform, which supports patient recovery through continuous data collection, and the Persona IQ®, a smart knee implant for gathering kinematic data. The ROSA® Knee system received improvements for better surgical outcomes. COO Ivan Tornos highlighted the potential of these innovations to enhance decision-making and patient care.

Zimmer Biomet reported Q4 2022 net sales of $1.825 billion, up 2.7% year-over-year, with an 8.3% increase on a constant currency basis. The Q4 diluted loss per share was $0.62, whereas adjusted diluted EPS was $1.88. For the full year, net sales reached $6.940 billion, a 1.6% increase, and an adjusted EPS of $6.89. The company anticipates a 2023 revenue growth of 1.5% - 3.5% and adjusted EPS between $6.95 - $7.15. Recent highlights include FDA clearance for the Persona OsseoTi Keel Tibia and the acquisition of Embody, Inc.

Zimmer Biomet Holdings, Inc. (ZBH) announced its fourth quarter earnings conference call scheduled for February 3, 2023, at 8:30 a.m. ET. A news release detailing quarterly results will be available at 6:30 a.m. ET that day. Participants can access the live audio webcast via Zimmer Biomet's Investor Relations website. Those in the U.S. and Canada can join by dialing (888) 204-4368, while international callers should dial +1 (323) 994-2093 with conference ID 5103691.

Zimmer Biomet (ZBH) announced a definitive agreement to acquire Embody, Inc. for $155 million at closing and up to an additional $120 million based on future milestones. This acquisition aims to enhance Zimmer Biomet's sports medicine portfolio, notably through Embody's collagen-based solutions for orthopedic injuries, including the TAPESTRY^® implants. The deal is expected to drive revenue growth while being slightly dilutive to adjusted earnings per share in 2023. Completion is anticipated in February 2023.

Zimmer Biomet Holdings (ZBH) has declared a quarterly cash dividend of $0.24 per share for Q4 2022, payable on January 31, 2023, to stockholders on record as of December 27, 2022. This decision reflects the company's commitment to returning value to its investors and underscores its financial stability. With a rich history of over 90 years in the medical technology sector, Zimmer Biomet continues to innovate and expand its product offerings globally.

Zimmer Biomet Holdings (NYSE: ZBH) announces its participation in two significant conferences. Members of the Executive Management Team will present at the Goldman Sachs CEOs Unscripted Conference on January 5, 2023, at 11:25 a.m. ET, and at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:45 p.m. PT / 6:45 p.m. ET. A live webcast will be available on the company's Investor Relations website and archived for later access.

Zimmer Biomet's recent one-year study confirms that the mymobility platform using Apple Watch provides comparable outcomes to traditional care for knee replacement patients. The study, involving 401 patients, indicates significant reductions in outpatient physical therapy visits and emergency department visits related to surgery. Key results include a 60.6% rate of post-operative PT among mymobility users versus 94.6% in the control group, and a 1.3% surgery-related ED visit rate compared to 5.4% for controls. These findings, presented at the AAHKS annual meeting, may suggest cost-saving potential in patient care.